Aktienanalyse zu Can Fite Biopharma Ltd (CANF)CANFCan Fite Biopharma Ltd

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Can Fite Biopharma Ltd (CANF) is not a good buy. The stock is trading at $1.62, significantly down from its 52-week high of $12.30, which reflects a staggering 80.18% decline over the past year. The RSI is at 34.499, indicating that the stock is oversold, but the forward P/E ratio is 2.9665, suggesting that the stock may still be undervalued. However, the company continues to report substantial net losses, with a net income of -2,300,500 USD in Q2 2026. The main risk is the ongoing operating losses and the negative sentiment reflected in the 20-day change of -14.74%.

2 analysts cover CANF: 2 rate it Buy, 0 Hold and 0 Sell.